Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus Docetaxel in First-Line mCRPC
NCT03761225Phase 3Completed
- Sponsor
- AB Science
- Start
- Sep 2014
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Masitinib & docetaxel with Placebo & docetaxel (2 arms). Primary endpoint: Progression Free Survival up to 60 months. Started Sep 2014; status: completed.
02
Drugs
masitinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03761225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761225.